FDA warns Ranbaxy U.S. unit
This article was originally published in The Tan Sheet
Executive Summary
Ohm Labs' liquid manufacturing plant in Gloversville, N.Y., draws an FDA warning letter for good manufacturing practice deviations. The subsidiary of Indian pharma Ranbaxy acknowledged receiving the letter in a Dec. 24 release, adding the GMP violations were discovered during FDA inspections in July and August 2009. FDA found two other U.S. Ohm plants compliant during 2009 inspections, the North Brunswick, N.J., firm said. Ohm sells and distributes private-label and OTC products in the U.S